(Total Views: 688)
Posted On: 08/08/2020 1:43:02 AM
Post# of 72440
Well you are right, you never know for sure until you test the drug on humans.
My feeling is HHA and NIAID knew an antiviral was an important part of the Covid 19 therapeutic equation. When they reviewed the alternatives it was apparent Remdesivir was the best antiviral which could be quickly tested, manufactured, and dispensed as a treatment.
They have been roundly [as well as rightly] criticized for giving it a pass in its first big clinical trial where after the first few weeks they eliminated the control group and late in the trial changed the primary end point from mortality, after it was plainly struggling to meet, to length of hospital stay.
https://www.statnews.com/2020/05/11/inside-th...vir-study/
Of course these decisions are difficult in the middle of a pandemic, but not having a control group causes the study to lose its scientific validity. The control group would have likely had patients survive even though they were severely ill and the physicians managing their care were making changes in their supportive treatments which were also reducing mortality. This study will be questioned for years.
The result is for the next 6 months to a year Remdesivir will be a part of virtually every clinical trial which makes the task of finding the best treatments uselessly delayed.
IMO it is vitally important for Brilacidin to be in human clinical trials as soon as possible. Its in vitro studies have been great. Its multiple mechanisms of action seem tailor made for Covid19. IMO the the muddled Remdesivir [and Hydroxychloroquine trials] have lowered the bar for success so Brilacidin has a terrific chance for success.
As the RBL finishes its studies the next few weeks, it promises to bring exciting news about Brilacidin, We will soon know its SI, and the preview of the peer reviewed publications will reveal more data, and perhaps the direct in vitro comparison to Remdesivir.
JMO
GLTA, Farrell
My feeling is HHA and NIAID knew an antiviral was an important part of the Covid 19 therapeutic equation. When they reviewed the alternatives it was apparent Remdesivir was the best antiviral which could be quickly tested, manufactured, and dispensed as a treatment.
They have been roundly [as well as rightly] criticized for giving it a pass in its first big clinical trial where after the first few weeks they eliminated the control group and late in the trial changed the primary end point from mortality, after it was plainly struggling to meet, to length of hospital stay.
https://www.statnews.com/2020/05/11/inside-th...vir-study/
Of course these decisions are difficult in the middle of a pandemic, but not having a control group causes the study to lose its scientific validity. The control group would have likely had patients survive even though they were severely ill and the physicians managing their care were making changes in their supportive treatments which were also reducing mortality. This study will be questioned for years.
The result is for the next 6 months to a year Remdesivir will be a part of virtually every clinical trial which makes the task of finding the best treatments uselessly delayed.
IMO it is vitally important for Brilacidin to be in human clinical trials as soon as possible. Its in vitro studies have been great. Its multiple mechanisms of action seem tailor made for Covid19. IMO the the muddled Remdesivir [and Hydroxychloroquine trials] have lowered the bar for success so Brilacidin has a terrific chance for success.
As the RBL finishes its studies the next few weeks, it promises to bring exciting news about Brilacidin, We will soon know its SI, and the preview of the peer reviewed publications will reveal more data, and perhaps the direct in vitro comparison to Remdesivir.
JMO
GLTA, Farrell
(7)
(0)Scroll down for more posts ▼
